Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy
We sought to compare frequency and duration of hepatic encephalopathy-related hospitalizations during rifaximin versus lactulose treatment. Hospitalizations, clinical efficacy data, and adverse events obtained from charts of 145 patients with hepatic encephalopathy who received lactulose (30 cc twic...
Gespeichert in:
| Veröffentlicht in: | Digestive diseases and sciences 2007-03, Vol.52 (3), p.737-741 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 741 |
|---|---|
| container_issue | 3 |
| container_start_page | 737 |
| container_title | Digestive diseases and sciences |
| container_volume | 52 |
| creator | LEEVY, Carroll B PHILLIPS, James A |
| description | We sought to compare frequency and duration of hepatic encephalopathy-related hospitalizations during rifaximin versus lactulose treatment. Hospitalizations, clinical efficacy data, and adverse events obtained from charts of 145 patients with hepatic encephalopathy who received lactulose (30 cc twice daily) for > or = 6 months and then rifaximin (400 mg 3 times a day) for > or = 6 months compared last 6 months on lactulose (lactulose period) to first 6 months on rifaximin (rifaximin period). Fewer hospitalizations (0.5 versus 1.6; P < .001), fewer days hospitalized (2.5 versus 7.3; P < .001), fewer total weeks hospitalized (0.4 versus 1.8; P < .001), and lower hospitalization charges per patient ($14,222 versus $56,635) were reported during the rifaximin period. More patients had asterixis, diarrhea, flatulence, and abdominal pain during the lactulose period (P < .001). Treatment of hepatic encephalopathy with rifaximin was associated with lower hospitalization frequency and duration, lower hospital charges, better clinical status, and fewer adverse events. |
| doi_str_mv | 10.1007/s10620-006-9442-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70364536</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1217559221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-405940d6fc02ad4c59ce1574879bcb50721fd958103e04de7f9ed9c34b36061e3</originalsourceid><addsrcrecordid>eNp10UGP1CAYBmBiNO64-gO8mEajt-oHfND2aDbqmmziRc-EoR8Om7ZUoMb118s4k2xi4gkID2-Al7HnHN5ygO5d5qAFtAC6HRBFiw_YjqtOtkLp_iHbAdd1zrm-YE9yvgWAoeP6MbvgnUClRb9j4TrmNRQ7hd-2hLjkZtxSWL435UDNlqmJvknB219hDkvzk1LecjNZV7Yp1l0f019ZEtky01KO_kBrzXINLY7Wg51iXR7unrJH3k6Znp3HS_bt44evV9ftzZdPn6_e37QOFZQWQQ0Io_YOhB3RqcFRfRP23bB3ewWd4H4cVM9BEuBInR9oHJzEvdSgOclL9uaUu6b4Y6NczByyo2myC8Utmw6kRiV1ha_-gbdxS0u9mxFaowDUEqt6-V_FUSBwUBXxE3Ip5pzImzWF2aY7w8EcqzKnqkytyhyrMsfgF-fgbT_TeH_i3E0Fr8_AZmcnn-ziQr53ff0EBSj_AMX1m6k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>214240105</pqid></control><display><type>article</type><title>Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>LEEVY, Carroll B ; PHILLIPS, James A</creator><creatorcontrib>LEEVY, Carroll B ; PHILLIPS, James A</creatorcontrib><description>We sought to compare frequency and duration of hepatic encephalopathy-related hospitalizations during rifaximin versus lactulose treatment. Hospitalizations, clinical efficacy data, and adverse events obtained from charts of 145 patients with hepatic encephalopathy who received lactulose (30 cc twice daily) for > or = 6 months and then rifaximin (400 mg 3 times a day) for > or = 6 months compared last 6 months on lactulose (lactulose period) to first 6 months on rifaximin (rifaximin period). Fewer hospitalizations (0.5 versus 1.6; P < .001), fewer days hospitalized (2.5 versus 7.3; P < .001), fewer total weeks hospitalized (0.4 versus 1.8; P < .001), and lower hospitalization charges per patient ($14,222 versus $56,635) were reported during the rifaximin period. More patients had asterixis, diarrhea, flatulence, and abdominal pain during the lactulose period (P < .001). Treatment of hepatic encephalopathy with rifaximin was associated with lower hospitalization frequency and duration, lower hospital charges, better clinical status, and fewer adverse events.</description><identifier>ISSN: 0163-2116</identifier><identifier>EISSN: 1573-2568</identifier><identifier>DOI: 10.1007/s10620-006-9442-4</identifier><identifier>PMID: 17245628</identifier><identifier>CODEN: DDSCDJ</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Adult ; Antibacterial agents ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Biological and medical sciences ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Gastrointestinal Agents - economics ; Gastrointestinal Agents - therapeutic use ; Hepatic Encephalopathy - drug therapy ; Hepatic Encephalopathy - economics ; Hospitalization ; Hospitalization - economics ; Hospitalization - statistics & numerical data ; Humans ; Lactulose - economics ; Lactulose - therapeutic use ; Length of Stay ; Liver Cirrhosis - complications ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; New Jersey ; Other diseases. Semiology ; Pharmacology. Drug treatments ; Rifamycins - economics ; Rifamycins - therapeutic use ; Rifaximin</subject><ispartof>Digestive diseases and sciences, 2007-03, Vol.52 (3), p.737-741</ispartof><rights>2007 INIST-CNRS</rights><rights>Springer Science+Business Media, LLC 2007</rights><rights>Springer Science+Business Media, Inc. 2006.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-405940d6fc02ad4c59ce1574879bcb50721fd958103e04de7f9ed9c34b36061e3</citedby><cites>FETCH-LOGICAL-c450t-405940d6fc02ad4c59ce1574879bcb50721fd958103e04de7f9ed9c34b36061e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18581504$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17245628$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>LEEVY, Carroll B</creatorcontrib><creatorcontrib>PHILLIPS, James A</creatorcontrib><title>Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy</title><title>Digestive diseases and sciences</title><addtitle>Dig Dis Sci</addtitle><description>We sought to compare frequency and duration of hepatic encephalopathy-related hospitalizations during rifaximin versus lactulose treatment. Hospitalizations, clinical efficacy data, and adverse events obtained from charts of 145 patients with hepatic encephalopathy who received lactulose (30 cc twice daily) for > or = 6 months and then rifaximin (400 mg 3 times a day) for > or = 6 months compared last 6 months on lactulose (lactulose period) to first 6 months on rifaximin (rifaximin period). Fewer hospitalizations (0.5 versus 1.6; P < .001), fewer days hospitalized (2.5 versus 7.3; P < .001), fewer total weeks hospitalized (0.4 versus 1.8; P < .001), and lower hospitalization charges per patient ($14,222 versus $56,635) were reported during the rifaximin period. More patients had asterixis, diarrhea, flatulence, and abdominal pain during the lactulose period (P < .001). Treatment of hepatic encephalopathy with rifaximin was associated with lower hospitalization frequency and duration, lower hospital charges, better clinical status, and fewer adverse events.</description><subject>Adult</subject><subject>Antibacterial agents</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Biological and medical sciences</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gastrointestinal Agents - economics</subject><subject>Gastrointestinal Agents - therapeutic use</subject><subject>Hepatic Encephalopathy - drug therapy</subject><subject>Hepatic Encephalopathy - economics</subject><subject>Hospitalization</subject><subject>Hospitalization - economics</subject><subject>Hospitalization - statistics & numerical data</subject><subject>Humans</subject><subject>Lactulose - economics</subject><subject>Lactulose - therapeutic use</subject><subject>Length of Stay</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>New Jersey</subject><subject>Other diseases. Semiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Rifamycins - economics</subject><subject>Rifamycins - therapeutic use</subject><subject>Rifaximin</subject><issn>0163-2116</issn><issn>1573-2568</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp10UGP1CAYBmBiNO64-gO8mEajt-oHfND2aDbqmmziRc-EoR8Om7ZUoMb118s4k2xi4gkID2-Al7HnHN5ygO5d5qAFtAC6HRBFiw_YjqtOtkLp_iHbAdd1zrm-YE9yvgWAoeP6MbvgnUClRb9j4TrmNRQ7hd-2hLjkZtxSWL435UDNlqmJvknB219hDkvzk1LecjNZV7Yp1l0f019ZEtky01KO_kBrzXINLY7Wg51iXR7unrJH3k6Znp3HS_bt44evV9ftzZdPn6_e37QOFZQWQQ0Io_YOhB3RqcFRfRP23bB3ewWd4H4cVM9BEuBInR9oHJzEvdSgOclL9uaUu6b4Y6NczByyo2myC8Utmw6kRiV1ha_-gbdxS0u9mxFaowDUEqt6-V_FUSBwUBXxE3Ip5pzImzWF2aY7w8EcqzKnqkytyhyrMsfgF-fgbT_TeH_i3E0Fr8_AZmcnn-ziQr53ff0EBSj_AMX1m6k</recordid><startdate>20070301</startdate><enddate>20070301</enddate><creator>LEEVY, Carroll B</creator><creator>PHILLIPS, James A</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20070301</creationdate><title>Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy</title><author>LEEVY, Carroll B ; PHILLIPS, James A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-405940d6fc02ad4c59ce1574879bcb50721fd958103e04de7f9ed9c34b36061e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Antibacterial agents</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Biological and medical sciences</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gastrointestinal Agents - economics</topic><topic>Gastrointestinal Agents - therapeutic use</topic><topic>Hepatic Encephalopathy - drug therapy</topic><topic>Hepatic Encephalopathy - economics</topic><topic>Hospitalization</topic><topic>Hospitalization - economics</topic><topic>Hospitalization - statistics & numerical data</topic><topic>Humans</topic><topic>Lactulose - economics</topic><topic>Lactulose - therapeutic use</topic><topic>Length of Stay</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>New Jersey</topic><topic>Other diseases. Semiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Rifamycins - economics</topic><topic>Rifamycins - therapeutic use</topic><topic>Rifaximin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LEEVY, Carroll B</creatorcontrib><creatorcontrib>PHILLIPS, James A</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Digestive diseases and sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LEEVY, Carroll B</au><au>PHILLIPS, James A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy</atitle><jtitle>Digestive diseases and sciences</jtitle><addtitle>Dig Dis Sci</addtitle><date>2007-03-01</date><risdate>2007</risdate><volume>52</volume><issue>3</issue><spage>737</spage><epage>741</epage><pages>737-741</pages><issn>0163-2116</issn><eissn>1573-2568</eissn><coden>DDSCDJ</coden><abstract>We sought to compare frequency and duration of hepatic encephalopathy-related hospitalizations during rifaximin versus lactulose treatment. Hospitalizations, clinical efficacy data, and adverse events obtained from charts of 145 patients with hepatic encephalopathy who received lactulose (30 cc twice daily) for > or = 6 months and then rifaximin (400 mg 3 times a day) for > or = 6 months compared last 6 months on lactulose (lactulose period) to first 6 months on rifaximin (rifaximin period). Fewer hospitalizations (0.5 versus 1.6; P < .001), fewer days hospitalized (2.5 versus 7.3; P < .001), fewer total weeks hospitalized (0.4 versus 1.8; P < .001), and lower hospitalization charges per patient ($14,222 versus $56,635) were reported during the rifaximin period. More patients had asterixis, diarrhea, flatulence, and abdominal pain during the lactulose period (P < .001). Treatment of hepatic encephalopathy with rifaximin was associated with lower hospitalization frequency and duration, lower hospital charges, better clinical status, and fewer adverse events.</abstract><cop>Heidelberg</cop><pub>Springer</pub><pmid>17245628</pmid><doi>10.1007/s10620-006-9442-4</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0163-2116 |
| ispartof | Digestive diseases and sciences, 2007-03, Vol.52 (3), p.737-741 |
| issn | 0163-2116 1573-2568 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70364536 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adult Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Biological and medical sciences Female Gastroenterology. Liver. Pancreas. Abdomen Gastrointestinal Agents - economics Gastrointestinal Agents - therapeutic use Hepatic Encephalopathy - drug therapy Hepatic Encephalopathy - economics Hospitalization Hospitalization - economics Hospitalization - statistics & numerical data Humans Lactulose - economics Lactulose - therapeutic use Length of Stay Liver Cirrhosis - complications Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged New Jersey Other diseases. Semiology Pharmacology. Drug treatments Rifamycins - economics Rifamycins - therapeutic use Rifaximin |
| title | Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T05%3A07%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hospitalizations%20during%20the%20use%20of%20rifaximin%20versus%20lactulose%20for%20the%20treatment%20of%20hepatic%20encephalopathy&rft.jtitle=Digestive%20diseases%20and%20sciences&rft.au=LEEVY,%20Carroll%20B&rft.date=2007-03-01&rft.volume=52&rft.issue=3&rft.spage=737&rft.epage=741&rft.pages=737-741&rft.issn=0163-2116&rft.eissn=1573-2568&rft.coden=DDSCDJ&rft_id=info:doi/10.1007/s10620-006-9442-4&rft_dat=%3Cproquest_cross%3E1217559221%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=214240105&rft_id=info:pmid/17245628&rfr_iscdi=true |